Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Blepharitis – pipeline review, h2 2012


Published on announce 20% discount on this report Discount till 31st Dec. 2012 - Blepharitis – pipeline review, h2 2012

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Blepharitis – pipeline review, h2 2012

  1. 1. You can also request for sample page of abovemention reports on
  2. 2. Price :$ 2000 - PDF | $ 4000 - Site Licence | $ 6000 - Corporate LicencePages : 4020% Off on above $ 1000 Reports25% off on purchase of 2 reports and 30% on purchase of 3 ormore reports.Discount till 31st Dec. 2012.
  3. 3. SummaryGlobal Markets Direct’s, Blepharitis - Pipeline Review, H2 2012, provides anoverview of the indication’s therapeutic pipeline. This report providesinformation on the therapeutic development for Blepharitis, complete withlatest updates, and special features on late-stage and discontinued projects. Italso reviews key players involved in the therapeutic development forBlepharitis. Blepharitis - Pipeline Review, Half Year is built using data andinformation sourced from Global Markets Direct’s proprietary databases,Company/University websites, SEC filings, investor presentations and featuredpress releases from company/university sites and industry-specific third partysources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.
  4. 4. Scope- A snapshot of the global therapeutic scenario for Blepharitis. - A review of the Blepharitis products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources. - Coverage of products based on various stages of development ranging fromdiscovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Blepharitis.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the mostpromising pipeline.
  5. 5. Table Of ContentsList of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Blepharitis Overview 6Therapeutics Development 7An Overview of Pipeline Products for Blepharitis 7Blepharitis Therapeutics under Development by Companies 9Blepharitis Therapeutics under Investigation by Universities/Institutes 10Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13Comparative Analysis 13Pre-Clinical Stage Products 14Comparative Analysis 14………………
  6. 6. More Related Reports: Ophthalmological Disorders – Pipeline Review, H2 2012Bacterial Respiratory Tract Infections – Pipeline Review, H2 2012Allergic Asthma – Pipeline Review, H2 2012Fibrosis – Pipeline Review, H2 2012X Chromosome Disorders – Pipeline Review, H2 2012
  7. 7. For More details about above & other Reportsplz contact :LavanyaAarkstore.comContact: Marketing teamMob.No.918149852585Email: enquiry@aarkstore.comURL: http://www.aarkstore.com